115 related articles for article (PubMed ID: 8212060)
1. Optimization issues in physiological toxicokinetic modeling: a case study with benzene.
Woodruff TJ; Bois FY
Toxicol Lett; 1993 Aug; 69(2):181-96. PubMed ID: 8212060
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three physiologically based pharmacokinetic models of benzene disposition.
Bois FY; Woodruff TJ; Spear RC
Toxicol Appl Pharmacol; 1991 Aug; 110(1):79-88. PubMed ID: 1871774
[TBL] [Abstract][Full Text] [Related]
3. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results.
Spear RC; Bois FY
Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):61-6. PubMed ID: 7737043
[TBL] [Abstract][Full Text] [Related]
4. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications.
Spear RC; Bois FY; Woodruff T; Auslander D; Parker J; Selvin S
Risk Anal; 1991 Dec; 11(4):641-54. PubMed ID: 1780503
[TBL] [Abstract][Full Text] [Related]
5. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis.
Cox LA
Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1413-29. PubMed ID: 9118928
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach.
Yokley K; Tran HT; Pekari K; Rappaport S; Riihimaki V; Rothman N; Waidyanatha S; Schlosser PM
Risk Anal; 2006 Aug; 26(4):925-43. PubMed ID: 16948686
[TBL] [Abstract][Full Text] [Related]
7. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method.
Thomas RS; Lytle WE; Keefe TJ; Constan AA; Yang RS
Fundam Appl Toxicol; 1996 May; 31(1):19-28. PubMed ID: 8998950
[TBL] [Abstract][Full Text] [Related]
8. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models.
Hack CE
Toxicology; 2006 Apr; 221(2-3):241-8. PubMed ID: 16466842
[TBL] [Abstract][Full Text] [Related]
9. Structure and parameterization of pharmacokinetic models: their impact on model predictions.
Woodruff TJ; Bois FY; Auslander D; Spear RC
Risk Anal; 1992 Jun; 12(2):189-201. PubMed ID: 1502372
[TBL] [Abstract][Full Text] [Related]
10. An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model.
Bois FY; Paxman DG
Regul Toxicol Pharmacol; 1992 Apr; 15(2 Pt 1):122-36. PubMed ID: 1626064
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism.
Bois FY; Smith MT; Spear RC
Toxicol Lett; 1991 May; 56(3):283-98. PubMed ID: 2035176
[TBL] [Abstract][Full Text] [Related]
12. Statistical issues in toxicokinetic modeling: a bayesian perspective.
Bernillon P; Bois FY
Environ Health Perspect; 2000 Oct; 108 Suppl 5():883-93. PubMed ID: 11035998
[TBL] [Abstract][Full Text] [Related]
13. Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data.
Nestorov I; Gueorguieva I; Jones HM; Houston B; Rowland M
Drug Metab Dispos; 2002 Mar; 30(3):276-82. PubMed ID: 11854145
[TBL] [Abstract][Full Text] [Related]
14. Interspecies extrapolation of physiological pharmacokinetic parameter distributions.
Watanabe KH; Bois FY
Risk Anal; 1996 Dec; 16(6):741-54. PubMed ID: 8972106
[TBL] [Abstract][Full Text] [Related]
15. Probabilistic biosphere modeling for the long-term safety assessment of geological disposal facilities for radioactive waste using first- and second-order Monte Carlo simulation.
Ciecior W; Röhlig KJ; Kirchner G
J Environ Radioact; 2018 Oct; 190-191():10-19. PubMed ID: 29734123
[TBL] [Abstract][Full Text] [Related]
16. Population toxicokinetics of benzene.
Bois FY; Jackson ET; Pekari K; Smith MT
Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1405-11. PubMed ID: 9118927
[TBL] [Abstract][Full Text] [Related]
17. Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.
Valcke M; Haddad S
J Toxicol Environ Health A; 2015; 78(7):409-31. PubMed ID: 25785556
[TBL] [Abstract][Full Text] [Related]
18. PBTK model for assessment of operator exposure to haloxyfop using human biomonitoring and toxicokinetic data.
Cooper AB; Aggarwal M; Bartels MJ; Morriss A; Terry C; Lord GA; Gant TW
Regul Toxicol Pharmacol; 2019 Mar; 102():1-12. PubMed ID: 30543831
[TBL] [Abstract][Full Text] [Related]
19. The Bayesian population approach to physiological toxicokinetic-toxicodynamic models--an example using the MCSim software.
Jonsson F; Johanson G
Toxicol Lett; 2003 Feb; 138(1-2):143-50. PubMed ID: 12559698
[TBL] [Abstract][Full Text] [Related]
20. Consequences of using a simplified kinetic model for dynamic PET data.
Coxson PG; Huesman RH; Borland L
J Nucl Med; 1997 Apr; 38(4):660-7. PubMed ID: 9098221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
